Research in contextEvidence Before This StudyThere is an increasing interest in cost-effectiveness of HIV programming among stakeholders. The last systematic review on the cost-effectiveness of all HIV prevention interventions was published nearly ten years ago. At that time, cost-effectiveness studies were limited and often unavailable for specific interventions. A 2013 systematic review presented evidence from studies specifically on pre-exposure prophylaxis and concluded that the intervention\'s impact relied highly on contextual assumptions. In the past decade, an increasing number of cost-effectiveness studies in HIV prevention literature have become available, but there has not yet been a single review that synthesizes the evidence from all of these studies. We conducted a systematic review for cost-effectiveness studies on HIV prevention interventions. We searched PubMed/MEDLINE, Web of Science, Econ-Lit, Embase, and African Index Medicus, for studies published between January 1, 2009 and December 31, 2018. Search terms included "HIV", "prevention" or "control"; "sub-Saharan Africa"; "cost" or "cost-effectiveness".Added Value of This StudyThis is the first review that provides a comprehensive and update look at the cost-effectiveness of all HIV prevention interventions targeted towards HIV- individuals. Additionally, this review focuses solely on sub-Saharan Africa, the region that carries the vast majority of the global disease burden. We show that voluntary medical male circumcision (VMMC) and prevention of mother-to-child transmission (PMTCT) interventions are cost-effective in almost all contexts. We provide evidence of cost-effectiveness of other newer biomedical interventions, including pre-exposure prophylaxis (PrEP) and treatment as prevention (TasP). We hope that the evidence from this review will aid various stakeholders, including Ministries of Health, program implementers, and international donors, in their decision-making regarding resource allocation policy for HIV prevention.Implications of All the Available EvidenceThe number of studies included in this review reflects the increasing importance of considering cost-effectiveness when designing or implementing HIV prevention programs in sub-Saharan Africa. Numerous studies focused on new biomedical interventions, and many of these studies used mathematical modeling to provide evidence of these interventions\' cost-effectiveness since they have not yet been scaled up in sub-Saharan Africa. However, this review shows that most interventions can be cost-effective in specific contexts. As such, we encourage others to use the results of this review with caution. Future economic and costing studies on HIV prevention should include more realistic scenarios so that these data are more accessible and relevant to policymakers and other stakeholders.Alt-text: Unlabelled Box

1. Introduction {#s0025}
===============

Sub-Saharan Africa (SSA) has experienced a large reduction in new HIV infections over the last decade, with the number of incident infections dropping over 30% since 2010 [@bb0005]. This decrease in burden reflects the accomplishment of a global effort focused on a region in which approximately 70% of all people living with HIV reside [@bb0010], [@bb0015]. Despite this success, the decline in incidence is slowing, and gaps in the scale-up of HIV prevention services persist throughout SSA [@bb0015].

US\$4.5 billion was allocated for HIV prevention investments in 2016 by the international community; however, a recent UNAIDS report stated that an additional annual investment of US\$7 billion is urgently needed to meet the 2030 Sustainable Development Goals targets [@bb0020], [@bb0025], [@bb0030]. To improve the efficiency of programming for HIV prevention, optimizing limited financial resources is crucial to scale up high-quality, cost-effective interventions to maximize HIV prevention [@bb0035].

In addition to evidence-based prevention tools such as voluntary medical male circumcision (VMMC) and prevention of mother-to-child transmission (PMTCT) strategies, new prevention methods such as HIV pre-exposure prophylaxis (PrEP) have been heralded for their remarkable clinical results in the reduction of HIV transmission. However, it is important for policy- and decision-makers to identify where and how such costly interventions fit within regional and national HIV implementation plans and budgets, particularly in resource-limited countries [@bb0040].

Ascertaining the cost-effectiveness of prevention interventions is necessary for optimal resource allocation and for identifying inefficiencies within prevention programs [@bb0035].

A systematic review of HIV prevention intervention cost-effectiveness was published in 2009 by Galarraga et al., which concluded that the number and quality of cost-effectiveness studies were insufficient and too limited at that time to aid decision making and policy recommendations [@bb0045], [@bb0050]. However, since 2009, many studies have been published on the cost-effectiveness of various prevention interventions, including newer PrEP technologies and treatment-as-prevention [@bb0040].

No systematic review to date has evaluated these newer prevention interventions with a focus on SSA. Such a review would provide important information on HIV prevention costs, outcomes, and effectiveness to support policies and decision-making [@bb0040], [@bb0045]. The purpose of this review is to systematically review published analyses of the cost-effectiveness of HIV prevention interventions in SSA settings. We aim to 1) review evidence from studies published in the last decade that have evaluated cost and outcome metrics for HIV prevention interventions, 2) compare the costs and effects of specific prevention interventions, and 3) understand the assumptions driving cost-effectiveness in order to inform allocation of limited HIV prevention resources.

2. Methods {#s0030}
==========

2.1. Search Strategy and Selection Criteria {#s0035}
-------------------------------------------

We conducted this systematic review in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [@bb0050]. We searched PubMed/MEDLINE, Web of Science, Econ-Lit, Embase, and African Index Medicus. Additionally, we reviewed reference lists of retrieved articles as well as governmental and organizational reports to complement our search. We limited studies published between January 1, 2009 and December 31, 2018. The following keywords were used: "HIV"; "prevention" or "control"; "cost" or "cost-analysis" or "cost-effectiveness"; "sub-Saharan Africa". The full search strategy, including keywords for each database, can be found in the supplemental material.

Inclusion criteria included full articles that were peer-reviewed and published in English, and reported cost and outcome measures or analysed cost-effectiveness of an HIV prevention intervention. Interventions included, but were not limited to: VMMC, PMTCT, TasP, PrEP, behavioral interventions, vaccinations, and microbicides. As a multi-pronged strategy, two types of PMTCT interventions were considered: Prong II, interventions to prevent unintended pregnancies of HIV-positive women, and Prong III, interventions providing services to reduce HIV transmission from HIV-positive women to their infants. Geography was limited to country settings within SSA, as defined by the United Nations [@bb0055]. A full list of eligible country settings can be found in the supplemental material. Studies that focused on HIV treatment with no prevention aspect, systematic reviews, meta-analyses, conference abstracts, and guideline reports were excluded. Studies assessing cost-effectiveness of an intervention\'s combined impact for both HIV-positive and HIV-negative persons and studies that did not describe costing analyses and effectiveness measures were excluded. Two reviewers aggregated a list of articles produced by the database search and conducted independent screenings based on title and abstract. All discrepancies were resolved by a third reviewer.

2.2. Quality Assessment and Data Extraction {#s0040}
-------------------------------------------

Two reviewers independently extracted data from each of the selected studies using a prepared data form, and an independent crosscheck by a third reviewer was conducted to identify and resolve any disagreements or uncertainties. We developed the data form using guidance from Emory colleagues and prior systematic reviews on similar topics. We assessed the quality of studies using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement, which contains a 24-point checklist to assess economic evaluation studies [@bb0060].

We extracted data on intervention type, study design or model type, geographic setting, HIV transmission method, population, intervention description, perspective, and time horizon. Additional extracted information included scenario descriptions, intervention effectiveness, cost-effectiveness metric results, and discounting rates for effects and costs. We categorized studies by prevention intervention type to compare intervention-specific results. The primary measures of interest were cost per HIV infection averted (HIA), cost per disability-adjusted life year (DALY) averted, cost per quality-adjusted life year (QALY) gained, and cost per life year gained (LYG). We converted study cost-effectiveness results to 2018 US\$ using the Consumer Price Index (CPI) Inflation Calculator and compared them to the International Monetary Fund 2018 estimates of gross domestic product (GDP) per capita for each study setting [@bb0065], [@bb0070].

For each intervention type, we calculated median CERs. Separate medians were calculated for studies reporting cost per HIA estimates and studies reporting cost per DALY averted, QALY gained, or LYG. For studies that explored more than one geographic setting, we considered results from the different settings as individual estimates if they were reported as such within a single study; these results were considered separately when we calculated median CERs.

3. Results {#s0045}
==========

We identified and screened 1115 articles, of which 146 met criteria to be assessed for eligibility. The 969 articles that were initially excluded were deemed ineligible based on the article title and abstract and did not meet either the geographic setting or intervention criteria. Out of the 146 articles, 60 met the full inclusion criteria ([Fig. 1](#f0005){ref-type="fig"}). These 60 peer-reviewed studies provided cost-effectiveness results for the following HIV prevention interventions: 14 studies on VMMC, 13 studies on PrEP, five studies on TasP, 15 studies on PMTCT, nine studies on other biomedical interventions, one study on behaviour change, and three studies on structural interventions [@bb0075], [@bb0080], [@bb0085], [@bb0090], [@bb0095], [@bb0100], [@bb0105], [@bb0110], [@bb0115], [@bb0120], [@bb0125], [@bb0130], [@bb0135], [@bb0140], [@bb0145], [@bb0150], [@bb0155], [@bb0160], [@bb0165], [@bb0170], [@bb0175], [@bb0180], [@bb0185], [@bb0190], [@bb0195], [@bb0200], [@bb0205], [@bb0210], [@bb0215], [@bb0220], [@bb0225], [@bb0230], [@bb0235], [@bb0240], [@bb0245], [@bb0250], [@bb0255], [@bb0260], [@bb0265], [@bb0270], [@bb0275], [@bb0280], [@bb0285], [@bb0290], [@bb0295], [@bb0300], [@bb0305], [@bb0310], [@bb0315], [@bb0320], [@bb0325], [@bb0330], [@bb0335], [@bb0340], [@bb0345], [@bb0350], [@bb0355], [@bb0360], [@bb0365], [@bb0370]. Among PMTCT studies, 14 considered Prong III strategies, while one focused on Prong II.Fig. 1Flowchart diagram for study selection.Fig. 1

[Table 1](#t0005){ref-type="table"} describes characteristics of each study, including study design or model type, geographic setting, method of transmission, target population, time horizon, HIV prevalence of the target population, perspective, and description of the intervention assessed. Studies focused on heterosexual transmission among the general population except for studies exploring prevention of mother-to-child-transmission. Costs were predominately assessed through a healthcare payer perspective. Two studies included results from countries outside of SSA; non-SSA results were excluded from this review [@bb0280], [@bb0310].Table 1Study design and setting overview.Table 1ReferenceStudy designSettingPopulationTime horizonHIV prevalence[a](#tf0005){ref-type="table-fn"}Perspective[b](#tf0010){ref-type="table-fn"}Intervention descriptionVMMCBinagwaho et al. (2010) [@bb0075]Deterministic compartmental simulationRwanda0-49 yo[c](#tf0015){ref-type="table-fn"}, male populationLifetime2.7%Health care payerScale-up of VMMC to infants, adolescents, and adultsNjeuhmeli et al. (2011) [@bb0080]Deterministic compartmental simulationSub-Saharan Africa15-49 yo, general populationLifetime4.8%Health care payerScale-up of VMMCUthman et al. (2011) [@bb0085]Probabilistic decision analysisSub-Saharan Africa15 + yo, male populationLifetime5.5%Health care payerUptake of VMMCDuffy et al. (2013) [@bb0090]Cross-sectional descriptive cost-analysisUganda18 yo and older, male populationLifetime5.9%Health care payerPrePex device for VMMCMenon et al. (2014) [@bb0095]Impact analysisTanzania10-49 yo, male populationLifetime4.5%Health care payerScale-up of VMMCAwad et al. (2015) [@bb0100]Deterministic compartmental simulationZimbabwe10-49 yo, male population15 years13.3%Health care payerPrioritisation of VMMC subpopulations by age, geographic location, sexual risk profileAwad et al. (2015) [@bb0105]Deterministic compartmental simulationZambia10-49 yo, male population15 years[c](#tf0015){ref-type="table-fn"}11.5%Health care payerPrioritisation of VMMC subpopulations by age, geographic location, sexual risk profileHaacker et al. (2016) [@bb0110]Deterministic compartmental simulationSouth Africa15-59, male populationLifetime18.8%Health care payerAge prioritised VMMC scale upKripke et al. (2016) [@bb0115]Deterministic compartmental simulationMalawi10 + yo; male population15 years9.6%Health care payerAge prioritised VMMC scale upKripke et al. (2016) [@bb0120]Deterministic compartmental simulationZimbabwe20-29 yo; male population15 years13.3%Health care payerAge prioritised VMMC scale upKripke et al. (2016) [@bb0125]Deterministic compartmental simulationSub-Saharan Africa10-49 yo; male population15 years4.8%Health care payerAge prioritised VMMC scale upKripke et al. (2016) [@bb0130]Deterministic compartmental simulationEswatini10-49 yo; male population15 years27.4%Health care payerAge prioritised VMMC scale upKripke et al. (2016) [@bb0135]Deterministic compartmental simulationMalawi, South Africa, Eswatini, Tanzania, Uganda10-49 yo; male population15 years9.6% (Malawi)\
18.8% (South Africa)\
27.4% (Eswatini)\
4.5% (Tanzania)\
5.9% (Uganda)Health care payerAge prioritised VMMC scale upNjeuhmeli et al. (2016) [@bb0140]Deterministic compartmental simulationZimbabweMale infants36 years13.3%Health care payerEarly infant male circumcision  PrEPPretorius et al. (2010) [@bb0145]Deterministic compartmental simulationSouth Africa15-49 yo, general population10 years18.8%Health care payerPrEP is scaled up to recruit all uninfected individualsHallett et al. (2011) [@bb0150]MicrosimulationSouth AfricaHIV serodiscordant couplesLifetime18.8%Health care payerPrEP for uninfected partner in serodiscordant relationshipsCremin et al. (2013) [@bb0155]Deterministic compartmental simulationKwaZulu-Natal, South Africa15-54 yo, general population10 years27.0% (KZN[c](#tf0015){ref-type="table-fn"})[^ref^](http://www.hsrc.ac.za/uploads/pageContent/9234/SABSSMV_Impact_Assessment_Summary_ZA_ADS_cleared_PDFA4.pdf){#ir0005}ProgramCombination prevention strategies of VMMC, early ART, and PrEPNichols et al. (2013) [@bb0160]Deterministic compartmental simulationMacha, Zambia12 + yo, general population10 years7.7% (Macha)Health care payerPrioritisation of PrEPVerguet et al. (2013) [@bb0165]Deterministic compartmental simulationSub-Saharan Africa15-49 yo, general population5 years4.8%Health care payerPrEP intervention to pre-existing levels of MC, ART, and condom useAlistar et al. (2014) [@bb0170]Dynamic compartmental simulationSouth Africa15-49 yo, general population20 years18.8%Health care payerPrEP is scaled up to recruit all uninfected individualsNichols et al. (2014) [@bb0175]Deterministic compartmental simulationMacha, Zambia12 + yo, general population40 years7.7% (Macha)Health care payerUptake of PrEP and TasP in combinationCremin et al. (2015) [@bb0180]Deterministic compartmental simulationNyanza province, KenyaGeneral population5 years13.9% (Nyanza)Health care payerDynamic interaction between key determinants of PrEP impact and cost-effectivenessCremin et al. (2015) [@bb0185]Deterministic compartmental simulationGaza province, MozambiqueAdult male mine workers5 years30.0% (female)\
17.0% (male)Health care payerTime-limited PrEP uptake among sexual partners of minersYing et al. (2015) [@bb0190]Micro-costing analysisUgandaHIV serodiscordant couples10 years7.1%ProgramTargeted PrEP for serodiscordant couplesGlaubius et al. (2016) [@bb0195]Deterministic compartmental simulationSouth Africa15-54 yo, general population1) 10yrs\
2) lifetime18.8%SocietalLong-acting injective antiretrovirals used for PrEPWalensky et al. (2016) [@bb0200]Deterministic compartmental simulationSouth Africa18-25 yo, high risk women5 yearsIncidence: 5.0% (high risk women)ProgramLong-acting PrEPCremin et al. (2017) [@bb0205]Deterministic compartmental simulationNairobi, KenyaKey populations10 years4.8%Health care payerPrEP provided to FSW  TasPBarnighausen et al. (2012) [@bb0210]Discrete time mathematical modelSouth Africa15 + yo, general population10 years18.8%Health care payerIncreased coverage of TasP, ART under the current WHO eligibility guidelines, and MMCGranich et al. (2012) [@bb0215]Deterministic compartmental simulationSouth Africa15 + yo, general population1) 5 years\
2) 40 years18.8%ProgramEnhanced combination prevention strategySmith et al. (2015) [@bb0220]Individual-based simulation modelling studyKwaZulu-Natal, South Africa18 + yo, general population10 years27.0% (KZN)[^ref^](http://www.hsrc.ac.za/uploads/pageContent/9234/SABSSMV_Impact_Assessment_Summary_ZA_ADS_cleared_PDFA4.pdf){#ir0010}Health care payerHome HIV counselling and testingBershteyn et al. (2016) [@bb0225]Individual-based simulation modelling studySouth AfricaGeneral population20 years18.8%Health care payerAge-targeting outreach with HIV treatment and preventionYing et al. (2016) [@bb0230]Dynamic compartmental modelKwaZulu-Natal, South AfricaGeneral population10 years27.0% (KZN)[^ref^](http://www.hsrc.ac.za/uploads/pageContent/9234/SABSSMV_Impact_Assessment_Summary_ZA_ADS_cleared_PDFA4.pdf){#ir0015}ProgramHome HIV testing and counselling  PMTCTHalperin et al. (2009) [@bb0235]Modelling analysisSub-Saharan AfricaPregnant, HIV-infected women1 year4.8%Service deliveryAntiretroviral prophylaxis programs and family planning programsNakakeeto et al. (2009) [@bb0240]Forecasting modelBurkina Faso, Cameroon,\
Cote d'Ivoire,\
Malawi, Rwanda, Tanzania, and ZambiaHIV-infected women, HIV-exposed infants8 years0.8% (Burkina Faso)\
3.7% (Cameroon)\
2.8% (Cote d'Ivoire)\
9.6% (Malawi)\
2.7% (Rwanda)\
4.5% (Tanzania)\
11.5% (Zambia)Health care payerPMTCT package including: family planning, HIV testing and counselling, and provision of antiretroviral and cotrimoxazole prophylaxisOrlando et al. (2010) [@bb0245]Cost-effectiveness analysisMalawiPregnant, HIV-infected women42 months16.9% (ANC)Societal and PrivateHAART-based interventionRobberstad et al. (2010) [@bb0250]Decision analysisTanzaniaPregnant, HIV-infected women18 months6.6% (ANC)Health care payerHAART-based interventionShah et al. (2011) [@bb0255]Decision-based analytical modelNigeriaPregnant, HIV-infected women1 year2.8%Health care payer2009 WHO PMTCT guidelines (long-course ART)Kuznik et al. (2012) [@bb0260]Cost-effectiveness analysisUgandaPregnant, HIV-infected women19.3 years7.1%Health care payerCombination ARTBinagwaho et al. (2013) [@bb0265]Cost-effectiveness analysisRwandaHIV-infected pregnant women and their infantsLifetime2.7%Health care payerDual ARV and short course HAART prophylaxis with breastfeeding or replacement feedingFasawe et al. (2013) [@bb0270]Decision analysisMalawiPregnant, HIV-infected women10 years16.9% (ANC)Health care payerImplementation of Option B +Maredza et al. (2013) [@bb0275]Cost-effectiveness analysisSouth AfricaPregnant, HIV-infected women24 months28.0% (ANC)Health care payerHAART-based interventionGopalappa et al. (2014) [@bb0280]Deterministic compartmental simulationKenya, South Africa, Zambia15-49 yo, female populationLifetime5.9% (Kenya)\
18.8% (South Africa)\
11.5% (Zambia)ProgramImplementation of Option B +Ishikawa et al. (2014) [@bb0285]Decision analysisZambiaPregnant, HIV-infected women18 months11.5%Health care payerComparison between Option A, Option B, and Option B +Yu et al. (2014) [@bb0290]Decision analysisSouth AfricaPregnant, HIV-infected women18 months28.0% (ANC)Health care payer1) tested and treated promptly at any time during pregnancy (promptly treated cohort), 2) no testing or treatment until after delivery and appropriate standard treatments were offered (remedy treated cohort)Zulliger et al. (2014) [@bb0295]Cost-effectiveness analysisSouth AfricaPregnant, HIV-infected women1 year28.0% (ANC)Health care payerExpedited initiation onto lifelong ART in pregnant women who met South African ART eligibility criteriaPrice et al. (2016) [@bb0300]Decision analysisZambiaPregnant womenLifetime11.5%Health care payerDaily oral PrEP during pregnancy and breastfeedingTweya et al. (2016) [@bb0305]Individual-based simulation modelling studyMalawiPrimigravida women50 years16.9% (ANC)Health care payerOption B vs. Option B +  Other biomedicalVerguet et al. (2010) [@bb0310]Cost-effectiveness analysisSouth Africa15-49 yo, female population1 year26.3% (Female)Health care payerImpact of microbicides distributed alongside condomsWilliams et al. (2011) [@bb0315]Dynamic compartmental modelSouth AfricaGeneral population20 years18.8%Health care payerTenofovir gel uptake by sexually active womenLong et al. (2013) [@bb0320]Dynamic compartmental simulationSouth Africa15-49 yo, general population10 years18.8%Health care payerHIV screening and counselling, ART, VMMC, microbicidesMbah et al. (2013) [@bb0325]Dynamic compartmental simulationZimbabwe15-49 yo, female population10 years13.3%Health care payerPraziquantel as a preventive\
anthelminthic chemotherapyTerris-Prestholt et al. (2014) [@bb0330]Deterministic compartmental simulationGauteng Province, South Africa15-49 yo, general population +\
FSW and their partners15 years17.6% (Gauteng)Health care payerUptake of tenofovir gel by womenMvundura et al. (2015) [@bb0335]Impact analysisSub-Saharan Africa15-49 yo, general population1 year4.8%Health care payerDistribution of 100,000 female condomsMoodley et al. (2016) [@bb0340]Semi-Markov simulationSouth AfricaAdolescents enrolled in schoolLifetime10.2% (females 15-24)\
3.9% (males 15-24)Health care payerHypothetical HIV vaccination provided to adolescent studentsMoodley et al. (2016) [@bb0345]Semi-Markov simulationSouth AfricaAdolescents girls enrolled in schoolLifetime10.2% (females 15-24)\
3.9% (males 15-24)Health care payerNational implementation of hypothetical HIV vaccination to adolescentsWall et al. (2018) [@bb0350]Cost-benefit analysis and cost-effectiveness analysisZambiaHIV serodiscordant couples5 years11.5%DonorCouples' testing and counselling with TasP for seropositive partner  Behavior changeEnns et al. (2011) [@bb0355]Stochastic network simulationEswatini, Tanzania, Uganda, Zambia15-49 yo, general population10 years27.4% (Eswatini)\
4.7% (Tanzania)\
7.1% (Uganda)\
11.5% (Zambia)ProgramConcurrency reduction campaigns focused on behaviour change scenario: 1) increased monogamy, 2) high-risk partnership reduction, 3) untargeted partnership reduction  StructuralFieno et al. (2014) [@bb0360]Cost simulationSouth AfricaWomen aged 15-20 yo, bottom quarter of income distribution6 years18.8%Health care payerCash transfersRemme et al. (2014) [@bb0365]Cost-benefit analysis and cost-effectiveness analysisMalawiAdolescent girls attending school18 months9.6%Health care payerCash transfersRutstein et al. (2014) [@bb0370]Decision-tree modelMalawi15-49 yo, partners of STI clinic indexes1 year9.6%Health care payerPartner notification[^1][^2][^3]

We extracted and converted each study\'s reported cost-effectiveness measure and converted them to 2018 US\$. [Table 2](#t0010){ref-type="table"} describes these measures. Most studies provided discounted results, with discounting ranging from 0%--5% for the base case scenario, as is standard in cost-effectiveness literature [@bb0185]. Outcome measures were presented as number of HIV infections averted (HIA) for a specific scenario, with fewer studies reporting quality-adjusted life years (QALYs) gained or disability-adjusted life years (DALYs) averted. A number of studies did not provide numerical values for cost-effectiveness measures but rather stated whether an intervention was a dominant (cost-savings with better outcomes) or dominated (costlier with poorer outcomes) strategy [@bb0275], [@bb0290], [@bb0335]. The most cost-effective interventions included -\$8356 per HIA for a microbicide intervention in South Africa, −\$312 per HIA for a PMTCT intervention in Malawi, and \$470 per HIA for a VMMC intervention in Uganda [@bb0090], [@bb0245], [@bb0310].Table 2Intervention cost and output results.Table 2ReferenceScenarioOutcome measureCost-effectiveness measure reported in publication (US\$)Cost-effectiveness measure (US\$ 2018)Discount rateCountry GDP per capita (current US\$), 2018[a](#tf0020){ref-type="table-fn"}[@bb0380]VMMCBinagwaho et al. (2010) [@bb0075]Infants1288 HIA[l](#tf0075){ref-type="table-fn"}Cost-saving\--3%Rwanda: \$800 ⋅ 21Adolescents1283 HIACER[l](#tf0075){ref-type="table-fn"} = \$3,932/HIA\$4,698/HIAAdults859 HIACER = \$4,949/HIA\$5,914/HIANjeuhmeli et al. (2011) [@bb0080]80% VMMC coverage in 13 countries9 VMMCs/1 HIA\$809/HIA\$927/HIANRSSA: \$1,620 ⋅ 00Uthman et al. (2011) [@bb0085]All adult males15 ⋅ 5 DALY[l](#tf0075){ref-type="table-fn"} averted/HIA\$-325/DALY averted (cost savings)\$-388/DALY averted3%SSA: \$1,620 ⋅ 00Duffy et al. (2013) [@bb0090]Surgical circumcision methodNR[m](#tf0080){ref-type="table-fn"}\$430/HIA\$470/HIANRUganda: \$717 ⋅ 50PrePex circumcision methodNR\$580/HIA\$634/HIAMenon et al. (2014) [@bb0095]Scale-up and maintenance of 80% VMMC coverageNR\$3,200/HIA\$3,668/HIA3%Tanzania: \$1,090 ⋅ 00Awad et al. (2015) [@bb0100]Current VMMC scale-up program326,000 HIA\
11 VMMCs/1 HIA (2010-2025)\$1,010/HIA\$1,072/HIA3%Zimbabwe: \$1,270 ⋅ 00VMMC program with subpopulation prioritization10-53 VMMCs/1 HIA\$811-\$5,518/HIA\$861-\$5,861/HIAAwad et al. (2015) [@bb0105]Current VMMC scale-up program306,000 HIA\
23 VMMCs/1 HIA (2010-2017)\
12 VMMCs/1 HIA (2017-2025)\$1,089/HIA\$1,156/HIA3%Zambia: \$1,145 ⋅ 00VMMC program with subpopulation prioritization11-36 VMMCs/1 HIA\$888-\$3300/HIA\$943-\$3505/HIAHaacker et al. (2016) [@bb0110]VMMC at 0 yo4 ⋅ 2 VMMCs/HIA\$859/HIA\$919/HIA5%South Africa: \$6,560 ⋅ 00VMMC at 20 yo4 ⋅ 4 VMMCs/HIA\$659/HIA\$705/HIAVMMC at 55 yo214 ⋅ 2 VMMCs/HIA\$24,157/HIA\$25,846/HIAKripke et al. (2016) [@bb0115]60% coverage among 10-29 yo79 HIA\$5,100/HIA\$5,307/HIA3%Malawi: \$349 ⋅ 1360% coverage among 10--34 yo92 HIA\$4,600/HIA\$4,786/HIA60% coverage among 10--49 yo106 HIA\$4,600/HIA\$4,786/HIA60% coverage among 15--49 yo104 HIA\$3,600/HIA\$3,746/HIA80% coverage among 15--49 yo148 HIA\$3,500/HIA\$3,642/HIAKripke et al. (2016) [@bb0120]80% Scenario: Scale up to 80% among 10-29 yo87,000 HIA\$4,800/HIA\$4,994/HIA3%Zimbabwe: \$1,270 ⋅ 00Base Scenario: Scale up to 80% among 10-19 yo63,000 HIA\$6,000/HIA\$6,243/HIAScenario A: 80% Scenario with 2x unit cost for 20-29 yo78,000 HIA\$6,600/HIA\$6,867/HIAScenario B: 80% Scenario with 2x unit costs for 20-24 yo and 3x unit costs for 25-29 yo83,000 HIA\$7,200/HIA\$7,492/HIAKripke et al. (2016) [@bb0125]Actual VMMC performance through 2014240,000 HIA (229,000, 572,000)\$4,400/HIA (median over 14 countries)\$4,578/HIA3% (costs only)SSA: \$1,620 ⋅ 0080% coverage among 15-49 yo1,082,000 HIA (744,000, 1,839,000)NR\--Kripke et al. (2016) [@bb0130]50% EIMC coverage/80% coverage among 10-24 yo20,000 HIA (14,000, 24,000)\$1,500/HIA (\$1,100, \$1,900)\$1,560/HIA (\$1,144, \$1,977)3%Eswatini: \$4,090 ⋅ 0050% EIMC coverage/80% coverage among 10-29 yo27,000 HIA (19,000, 34,000)\$1,300/HIA (\$900, \$1,600)\$1,352/HIA (\$936, \$1,664)50% EIMC coverage/80% coverage among 10-34 yo29,000 HIA (21,000, 38,000)\$1,200/HIA (\$900, \$1,600)\$1,248/HIA (\$936, \$1,664)Kripke et al. (2016) [@bb0135]80% coverage among 10-49 yoMalawi: 149,000 HIA\$4,600/HIA\$4,600/HIAMalawi: \$349 ⋅ 13\
South Africa: \$6,560 ⋅ 00\
Eswatini: \$4,090 ⋅ 00\
Tanzania: \$1,090 ⋅ 00\
Uganda: \$717 ⋅ 50South Africa: 375,000 HIA\$2,700/HIA\$2,700/HIAEswatini: 31,500 HIA\$1,200/HIA\$1,200/HIATanzania: 53,400 HIA\$5,800/HIA\$5,800/HIAUganda: 486,000 HIA\$1,500/HIA\$1,500/HIA80% coverage among 15-49 yoMalawi: 148,000 HIA\$3,500/HIA\$3,500/HIASouth Africa: 372,000 HIA\$2,200/HIA\$2,200/HIAEswatini: 32,200 HIA\$900/HIA\$900/HIATanzania: 50,500 HIA\$4,100/HIA\$4,266/HIAUganda: 475,000 HIA\$1,100/HIA\$1,144/HIA80% coverage among 15-24 yoMalawi: 82,000 HIA\$4,300/HIA\$4,474/HIASouth Africa: 182,000 HIA\$2,500/HIA\$2,601/HIAEswatini: 18,900 HIA\$1,000/HIA\$1,040/HIATanzania: 28,300 HIA\$4,900/HIA\$5,098/HIAUganda: 241,000 HIA\$1,400/HIA\$1,456/HIA80% coverage among 15-29 yoMalawi: 109,000 HIA\$3,700/HIA\$3,850/HIASouth Africa: 246,000 HIA\$2,200/HIA\$2,289/HIAEswatini: 25,700 HIA\$900/HIA\$936/HIATanzania: 36,200 HIA\$4,300/HIA\$4,474/HIAUganda: 324,000 HIA\$1,200/HIA\$1,248/HIA80% coverage among 15-34 yoMalawi: 128,000 HIA\$3,500/HIA\$3,642/HIASouth Africa: 303,000 HIA\$2,100/HIA\$2,185/HIAEswatini: 29,700 HIA\$900/HIA\$936/HIATanzania: 43,200 HIA\$4,000/HIA\$4,162/HIAUganda: 388,000 HIA\$1,100/HIA\$1,144/HIA80% coverage among 10-24 yoMalawi: 83,000 HIA\$6,100/HIA\$6,347/HIASouth Africa: 190,000 HIA\$3,600/HIA\$3,746/HIAEswatini: 19,600 HIA\$1,400/HIA\$1,456/HIATanzania: 31,300 HIA\$7,800/HIA\$8,116/HIAUganda: 256,000 HIA\$2,100/HIA\$2,185/HIA80% coverage among 10-29 yoMalawi: 110,000 HIA\$5,100/HIA\$5,307/HIASouth Africa: 250,000 HIA\$3,000/HIA\$3,121/HIAEswatini: 26,300 HIA\$1,200/HIA\$1,248/HIATanzania: 38,700 HIA\$6,800/HIA\$7,076/HIAUganda: 337,000 HIA\$1,700/HIA\$1,769/HIANjeuhmeli et al. (2016) [@bb0140]Scale up of VMMC among adolescents266,000 HIA\$4,127/HIA\$4,415/HIA3%Zimbabwe: \$1,270 ⋅ 00Introduction of EIMC into existing VMMC program268,000 HIA\$5,256/HIA\$5,623/HIA  PrEPPretorius et al. (2010) [@bb0145]Targeted PrEP for 25-35 yo womenNR\$12,500 - \$20,000/HIA\$14,328 - \$22,924/HIANRSouth Africa: \$6,560 ⋅ 00Hallett et al. (2011) [@bb0150]PrEP always used after HIV diagnosis in serodiscordant couple15% - 52% HIA\$0 - \$26,000/HIA\$0 - \$28,944/HIA3%South Africa: \$6,560 ⋅ 00PrEP used up through ART initiation for HIV infected partner11% - 36% HIA\$-2,200 - \$21,000/HIA\$-2,449 - \$26,025/HIAPrEP used only during periods of trying to conceive a pregnancy and during pregnancy1% - 2% HIA\$-6,000 - \$8,000/HIA\$-6,679 - \$8,906/HIACremin et al. (2013) [@bb0155]PrEP provided to 7.3% of uninfected 15-24 yo3 ⋅ 2% HIA\$10,540/HIA\$11,362/HIA3%South Africa: \$6,560 ⋅ 00PrEP provided to 4.4% of uninfected 15-54 yo3 ⋅ 6% HIA\$9,390/HIA\$10,122/HIANichols et al. (2013) [@bb0160]Non-prioritized PrEP2,333 HIA;\
23,571 QALYs[l](#tf0075){ref-type="table-fn"} gained\$1,843/QALY gained\$2,051/QALY gained3%Zambia: \$1,145 ⋅ 00Prioritized PrEP3,200 HIA;\
36,216 QALYs gained\$323/QALY gained\$359/QALY gainedVerguet et al. (2013) [@bb0165]PrEP intervention200 - 94,100 HIA\
3,300 - 1,266,000 DALYs averted\$550 - \$44,600/DALY averted\$612 - \$49,651/DALY avertedNRSSA: \$1,620 ⋅ 00Alistar et al. (2014) [@bb0170]10% Guidelines ART, 50% Focused PrEP1,837,744 HIACER = cost savingCER = cost saving3%South Africa: \$6,560 ⋅ 0010% Guidelines ART, 100% Focused PrEP3,084,508 HIACER = cost savingCER = cost saving50% Guidelines ART, 100% General PrEP3,642,543 HIA\$163/QALY gained\$174/QALY gained100% Guidelines ART, 100% Focused PrEP3,840,111 HIA\$229/QALY gained\$245/QALY gained50% Universal ART, 100% Focused PrEP4,468,827 HIA\$276/QALY gained\$295/QALY gained100% Universal ART, 100% Focused PrEP4,663,411 HIA\$302/QALY gained\$323/QALY gained10% Guidelines ART, 50% General PrEP2,998,344 HIA\$1,172/QALY gained\$1,253/QALY gained10% Guidelines ART, 100% General PrEP3,381,214 HIA\$1,158/QALY gained\$1,239/QALY gainedNichols et al. (2014) [@bb0175]Treatment available at CD4 \< 500 cells/μL3388 HIA;\
40,643 QALYs gainedCER = \$62/QALY gained (\$46--\$75)\
ICER = \$62/QALY gained (\$46--\$75)CER = \$69/QALY gained (\$51--\$83)\
ICER = \$69/QALY gained (\$51--\$83)3%Zambia: \$1,145 ⋅ 00Prioritized PrEP (most sexually active)1502 HIA;\
13,611 QALYs gainedCER = \$4,103/QALY gained (\$2,890--\$5,803)\
ICER[l](#tf0075){ref-type="table-fn"} = dominatedCER = \$4,567/QALY gained (\$3,217 -- \$6,460)\
ICER = dominatedPrioritized PrEP (mostly sexually active and treatment available at CD4 \< 500 cells/μL)4494 HIA;\
50,936 QALYs gainedCER = \$1,153/QALY gained (\$686--\$1,756)\
ICER = dominatedCER = \$1,283/QALY gained (\$763--\$1,954)\
ICER = dominatedNon-prioritized PrEP (randomly distributed)4053 HIA;\
40,318 QALYs gainedCER = \$3,730/QALY gained (\$2,454--\$5,691)\
ICER = dominatedCER = \$4,152/QALY gained (\$2,731--\$6,335)\
ICER = dominatedNon-prioritized PrEP (randomly distributed and treatment available at CD4 \< 500 cells/μL)5894 HIA;\
67,835 QALYs gainedCER = \$2,253/QALY gained (\$1,672--\$3,188)\
ICER = dominatedCER = \$2,508/QALY gained (\$1,861--\$3,549)\
ICER = dominatedCremin et al. (2015) [@bb0180]Standard PrEP intervention (\$20 million budget)24,603 (\~ 11%) HIA\
(3,750 - 49,450)\$2,060 - \$36,360/HIA\$2,293 - \$40,478/HIA3%South Africa: \$6,560 ⋅ 00Cremin et al. (2015) [@bb0185]All uninfected women eligible to receive PrEPNR\$15,647/HIA\$17,419/HIA3%Mozambique: \$481 ⋅ 25Providing PrEP only to partners of minersNR\$71,374/HIA\$79,458/HIAProviding PrEP only to partners of miners and only during the last six weeks of the yearNR\$9,538/HIA\$10,618/HIAYing et al. (2015) [@bb0190]40% overall ART coverage[b](#tf0025){ref-type="table-fn"}; 10% coverage for persons with CD4 350-500 cells/μL94,000 HIARef.\--3%Uganda: \$717 ⋅ 50Increase ART Coverage (50% coverage for persons with CD4 350-500 cells/μL)104,000 HIADominated\--Targeted PrEP and ART to 90% serodiscordant couples120,000 HIA\$1,340/HIA\$1,466/HIAGlaubius et al. (2016) [@bb0195]Optimistic scenario,\
Non-prioritized PrEP1 ⋅ 6% - 9 ⋅ 1% HIA\$20,905 - \$22,022/HIA\
\$176,755 - \$181,734/LYG\$22,874 - \$24,096/HIA\
\$192,313 - \$198,856/LYG3%South Africa: \$6,560 ⋅ 00Optimistic scenario,\
Age-prioritized PrEP2 ⋅ 9% - 17 ⋅ 2% HIA\$10,880 - \$11,094/HIA\
\$84,418 - \$85,105/LYG\$11,905 - \$12,139/HIA\
\$92,371 - \$93,123/LYGOptimistic scenario,\
Risk-prioritized PrEP8 ⋅ 1% HIA\$11,094/HIA\
\$85,105/LYG\$12,139/HIA\
\$93,123/LYGConservative scenario,\
Non-prioritized PrEP1 ⋅ 0 - 5 ⋅ 5% HIA\$35,090 - \$37,137/HIA\
\$276,605 - \$284,781/LYG\$38,396 - \$40,635/HIA\
\$302,665 - \$311,611/LYGConservative scenario,\
Age-prioritized PrEP1 ⋅ 8 - 10 ⋅ 3% HIA\$18,429 - \$19,213/HIA\
\$133,428 - \$135,695/LYG\$20,165 - \$21,023/HIA\
\$145,999 - \$148,479/LYGConservative scenario,\
Risk-prioritized PrEP4 ⋅ 4% HIA\$1,242/HIA\
\$11,568/LYG\$1,359/HIA\
\$12,657/LYGWalensky et al. (2016) [@bb0200]Standard PrEP127 HIA\$10,100/HIA\
Cost saving (vs. no PrEP)\$10,806/HIA3%South Africa: \$6,560 ⋅ 00Long-acting PrEP156 HIA\$12,400/HIA\
Cost saving (vs. no PrEP)\$13,267/HIACremin et al. (2017) [@bb0205]50% PrEP coverage to all FSWNR\$65,160/HIA (95% CI: \$43,520 - \$95,250)\$66,404/HIA (95% CI: \$44,351 - \$97,069)0%Kenya: \$1,870 ⋅ 0050% PrEP coverage to high-risk FSWNR\$10,920/HIA (95% CI: \$4,700 - \$51,560)\$11,128/HIA (95% CI: \$4,789 - \$52,544)  TasPBarnighausen et al. (2012) [@bb0210]Coverage: 70% ART, 20% TasP, 45% MMC[l](#tf0075){ref-type="table-fn"}650,000 HIA (compared to 50% ART and 45% MMC)\$7,157/HIA\$7,813/HIA3%South Africa: \$6,560 ⋅ 00Coverage: 80% ART, 40% TasP, 45% MMC1,000,000 HIA\$7,482/HIA\$8,186/HIACoverage: 80% ART, 60% TasP, 45% MMC1,100,000 HIA\$7,937/HIA\$8,684/HIACoverage: 80% ART, 80% TasP, 45% MMC1,260,000 HIA\$8,370/HIA\$9,158/HIAGranich et al. (2012) [@bb0215]ART initiation at CD4 count ≤ 350 cells/μL vs. ≤ 200 cells/μL200,000-1,400,000 HIANR\--3%South Africa: \$6,560 ⋅ 00ART initiation at CD4 count \< 500 cells/mm^3^ vs. ≤ 350 cells/μL200,000-1,500,000 HIA\$182/DALY averted\$199/DALY avertedART initiation at all CD4 levels vs. CD4 count ≤ 500 cells/μL300,000-1,400,000 HIA\$1,381/DALY averted\$1,510/DALY avertedSmith et al. (2015) [@bb0220]High ART cost \| Low ART cost3%South Africa: \$6,560 ⋅ 00ART initiation at ≤ 200 cells/μL (vs. status quo)2,000 DALYs averted\$22,300/HIA \| \$12,900/HIA\
\$1,230/DALY averted \| \$414/DALY averted\$24,400/HIA \| \$14,115/HIA\
\$1,345/DALY averted \| \$453/DALY avertedART initiation at ≤ 350 cells/μL3,100 DALYs averted\$10,400/HIA \| \$4,210/HIA\
\$1,020/DALY averted \|\
\$788/DALY averted\$11,379/HIA \| \$4,606/HIA\
\$1,116/DALY averted \| \$851/DALY avertedART initiation at \< 500 cells/μL3,300 DALYs averted\$8,910/HIA \| \$2,780/HIA\
\$1,090/DALY averted \| \$342/DALY averted\$9,749/HIA \| \$3,041/HIA\
\$1,192/DALY averted \| \$374/DALY avertedUniversal ART3,300 DALYs averted\$8,190/HIA \| \$1,960/HIA\
\$1,300/DALY averted \| \$310/DALY averted\$8,961/HIA \| \$2,144/HIA\
\$1,422/DALY averted \| \$339/DALY avertedBershteyn et al. (2016) [@bb0225]Targeting 10-30 yoNR\$6,238/HIA\$6,491/HIA3%South Africa: \$6,560 ⋅ 00Targeting 20-30 yoNR\$5,031/HIA\$5,235/HIATargeting 22-27 yoNR\$4,279/HIA\$4,452/HIATargeting 25-27 yoNR\$3,967/HIA\$4,128/HIATargeting to full populationNR\$10,812/HIA\$11,250/HIAYing et al. (2016) [@bb0230]Base case (36% of HIV-infected people achieving viral suppression)Ref.Ref.\--3%South Africa: \$6,560 ⋅ 00Home HTC (48% of HIV-infected people achieving viral suppression)152,000 HIA\$3,290/HIA\$3,546/HIAHome HTC + High Viral Load (60% ART uptake if CD4 \> 350 cells/μL and VL \> 10,000 copies/mL)183,000 HIA\$3,320/HIA\$3,579/HIAHome HTC + CD4 (60% ART uptake if CD4 350--500 cells/μL)195,000 HIA\$2,960/HIA\$3,190/HIA  PMTCTHalperin et al. (2009) [@bb0235]Perinatal HIV transmission prevention program241,596 HIA\$543/HIA\$631/HIA by perinatal infectionNRSSA: \$1,620 ⋅ 00Services to prevent unintended pregnancies72,000 HIA\$359/HIA\$417/HIA by unintended pregnancyNakakeeto et al. (2009) [@bb0240]Meeting UNGASS[l](#tf0075){ref-type="table-fn"} targets for PMTCT by 2010NRBurkina Faso: \$2,292/HIA\$2,741/HIA3%Burkina Faso: \$734.03\
Cameroon: \$1,540 ⋅ 00\
Cote d'Ivoire: \$1,790 ⋅ 00\
Malawi: \$349 ⋅ 13\
Rwanda: \$800 ⋅ 21\
Tanzania: \$1,090 ⋅ 00\
Zambia: \$1,145 ⋅ 00Cameroon: \$1,366/HIA\$1,633/HIACote d'Ivoire: \$1,391/HIA\$1,663/HIAMalawi: \$965/HIA\$1,154/HIARwanda: \$1,085/HIA\$1,297/HIATanzania: \$1,068/HIA\$1,277/HIAZambia: \$829/HIA\$991/HIAOrlando et al. (2010) [@bb0245]PMTCT program with VCT, HAART, treatment of malnutrition, TB, malaria, STDs (private perspective)370 HIA\
10,449 DALYs averted\$998/HIA\
\$35 ⋅ 36/DALY averted\$1,193/HIA\
\$42 ⋅ 30/DALY averted3%Malawi: \$349 ⋅ 13PMTCT program with VCT, HAART, treatment of malnutrition, TB, malaria, STDs (public perspective)370 HIA\
10,449 DALYs averted\$-261/HIA\
\$-16 ⋅ 55/DALY averted\$-312/HIA\
\$-19 ⋅ 80/DALY avertedRobberstad et al. (2010) [@bb0250]Single-dose NVP[l](#tf0075){ref-type="table-fn"}0 ⋅ 00051 HIA (per pregnancy)\
0 ⋅ 0129 DALYs averted\$26,826/HIA\
\$1,071/DALY averted\$20,749/HIA\
\$1,227/DALY avertedNRTanzania: \$1,090 ⋅ 00PMTCT Plus[c](#tf0030){ref-type="table-fn"}0 ⋅ 00267 HIA (per pregnancy)\
0 ⋅ 067 DALYs averted\$7,204/HIA\
\$287/DALY averted\$8,257/HIA\
\$328/DALY avertedShah et al. (2011) [@bb0255]Current PMTCT Coverage (10% of all HIV-infected women)1400 HIA\$3,620/HIA\$4,149/HIA3%Nigeria: \$2,050 ⋅ 00Current ANC Coverage (58% of HIV-infected women)7680 HIA\$3,203/HIA\$3,671/HIAFull PMTCT Coverage (100% of HIV-infected women)14400 HIA\$3,167/HIA\$3,630/HIAKuznik et al. (2012) [@bb0260]18 months ART vs. sdNVP[l](#tf0075){ref-type="table-fn"}5 ⋅ 21 DALYs averted\$46/DALY averted\$51/DALY averted3%Uganda: \$717 ⋅ 5018 months ART vs. DT[l](#tf0075){ref-type="table-fn"}3 ⋅ 22 DALYs averted\$99/DALY averted\$110/DALY averted18 months ART vs. no treatment8 ⋅ 58 DALYs averted\$34/DALY averted\$37/DALY avertedLifetime ART vs. sdNVP19 ⋅ 2 DALYs averted\$205/DALY averted\$228/DALY avertedLifetime ART vs. DT11 ⋅ 87 DALYs averted\$354/DALY averted\$394/DALY avertedLifetime ART vs. no treatment31 ⋅ 6 DALYs averted\$172/DALY averted\$191/DALY avertedBinagwaho et al. (2013) [@bb0265]Dual ARV + breastfeedingNRDominated\--3%Rwanda: \$800 ⋅ 21Dual ARV + replacement feedingNRDominated\--Sc-HAART + 6 mo. breastfeedingNRDominated\--Sc-HAART + 12 mo. breastfeeding9,837 HIV uninfected children still alive\-\-\--Sc-HAART + 18 mo. breastfeeding9,292 HIV uninfected children still aliveICER = \$11,882/HIA (compared to 12 mo.)\$12,882/HIASc-HAART + replacement feedingNRDominated\--Fasawe et al. (2013) [@bb0270]Current Practice4,503 HIA\$816/HIA\
\$37/QALY gained\$935/HIA\
\$42/QALY gained3%Malawi: \$349 ⋅ 13Option A15,606 HIA\$844/HIA\
\$37/QALY gained\$967/HIA\
\$42/QALY gainedOption B15,997 HIA\$1,331/HIA\
\$60/QALY gained\$1,525/HIA\
\$68/QALY gainedOption B +15,997 HIA\$1,265/HIA\
\$57/QALY gained\$1,450/HIA\
\$65/QALY gainedMaredza et al. (2013) [@bb0275]Increase coverage of extended NVP to infants (rural)220 DALYs avertedDominantDominant3%South Africa: \$6,560 ⋅ 00Promote formula feeding (rural)420 DALYs averted\$1,300/DALY averted\$1,490/DALY avertedPromote breastfeeding (rural)160 DALYs avertedDominant\--Increase coverage of extended NVP to infants (urban)90 DALYs avertedDominant\--Promote formula feeding (urban)160 DALYs avertedDominant\--Promote breastfeeding (urban)-240 DALYs averted[d](#tf0035){ref-type="table-fn"}\$3,200/DALY averted\$3,667/DALY avertedGopalappa et al. (2014) [@bb0280]Option B + vs. Option ANR[e](#tf0040){ref-type="table-fn"}Kenya: \$6,015/ HIA\
South Africa: \$22,987/HIA\
Zambia: \$6,778/HIAKenya: \$6,763/HIA\
South Africa: \$25,590/HIA\
Zambia: \$7,545/HIA3%Kenya: \$1,870 ⋅ 00\
South Africa: \$6,560 ⋅ 00\
Zambia: \$1,145 ⋅ 00Ishikawa et al. (2014) [@bb0285]Option B7,176 HIA\$1,023/HIA\$1,094/HIA3%Zambia: \$1,145 ⋅ 00Option B +7,318 HIA\$1,254/HIA\$1,341/HIAYu et al. (2014) [@bb0290]Remedy cohort[f](#tf0045){ref-type="table-fn"}110 infant HIAExtended dominated[g](#tf0050){ref-type="table-fn"}\--3%South Africa: \$6,560 ⋅ 00Remedy cohort, breastfeed421 infant HIAExtended dominated\--Remedy cohort, replacement feed11 infant HIAExtended dominated\--Promptly treated cohort[h](#tf0055){ref-type="table-fn"}698 infant HIAUndominated[i](#tf0060){ref-type="table-fn"}\--Promptly treated cohort, breastfeed360 infant HIAExtended dominated\--Promptly treated cohort, replacement feed883 infant HIAUndominated\--Zulliger et al. (2014) [@bb0295]Rapid initiation of ART in Pregnancy pilot program16.88 QALYs saved\$1,160/QALY gained\$1,291/QALY gained3%South Africa: \$6,560 ⋅ 00Price et al. (2016) [@bb0300]Oral PrEP at first ANC visit with HIV- test and end with breastfeeding cessation381 HIA\$965/DALY averted\$1,025/DALY averted3%Zambia: \$1,145 ⋅ 00Tweya et al. (2016) [@bb0305]Option B + vs. Option B133 DALYs averted\$841/DALY averted\$875/DALY averted3%Malawi: \$349 ⋅ 13  Other biomedicalVerguet et al. (2010) [@bb0310]Access to condoms and microbicide effective at 55%1,908 HIA\$-6,712/HIA\$-8,356/HIANRSouth Africa: \$6,560 ⋅ 00Williams et al. (2011) [@bb0315]Tenofovir 25% Coverage250,000 HIA (20,000 -- 380,000)\$2,392/HIA (\$562-\$4,222)\$2,662/HIA (\$625-\$4,700)3%South Africa: \$6,560 ⋅ 00Tenofovir 90% Coverage1,100,000 HIA (60,000 -- 2,040,000)\$1,701/HIA (\$420-\$2,982)\$1,893/HIA (\$467-\$3,319)Long et al. (2013) [@bb0320]Scale-up of VMMC to 75% of all men12 ⋅ 1% HIACost-saving\--NRSouth Africa: \$6,560 ⋅ 00Tenofovir gel used by 50% of women14 ⋅ 1% HIA\$526/QALY gained\$602/QALY gainedUse of PrEP by 50% of all uninfected persons28 ⋅ 4% HIA\$9,009/QALY gained\$10,326/QALY gainedVMMC, microbicide, and PrEP43 ⋅ 5% HIA\$5,739/QALY gained\$6,578/QALY gainedMbah et al. (2013) [@bb0325]Praziquantel treatment received during childhood21,120 HIA\$259/HIA\$314/HIA3%Zimbabwe: \$1,270 ⋅ 00Praziquantel treatment received during childhood and FGS[l](#tf0075){ref-type="table-fn"} prevalence is reduced relative to those who did not receive treatment41,500 HIA\$132/HIA\$174/HIATerris-Prestholt et al. (2014) [@bb0330]72% microbicide gel use consistency and 54% HIV efficacy55,366 HIA\$297/DALY averted\$392/DALY averted3%South Africa: \$6,560 ⋅ 00Mvundura et al. (2015) [@bb0335]Distribution of 100,000 female condoms273 HIALower Bound: Cost Savings[j](#tf0065){ref-type="table-fn"}\
Higher Bound: \$154/DALY averted[k](#tf0070){ref-type="table-fn"}\--\
Higher Bound: \$168/DALY avertedNRSSA: \$1,620 ⋅ 00Moodley et al. (2016) [@bb0340]HIV vaccine intervention for school-based adolescents4 ⋅ 36 QALYs gained in lifetime\$43/QALY gained\$47/QALY gained3%South Africa: \$6,560 ⋅ 00Moodley et al. (2016) [@bb0345]60% coverage at \$12 per vaccine doseNR\$4 ⋅ 98/LYG (95%: \$2 ⋅ 77--\$11 ⋅ 61)\$5 ⋅ 45/LYG (95%: \$3 ⋅ 03--\$12 ⋅ 70)3%South Africa: \$6,560 ⋅ 00Wall et al. (2018) [@bb0350]Nationwide CVCT166,153 HIA\$394/HIA\$394/HIA0%Zambia: \$1,145 ⋅ 00TasP for serodiscordant couples identified by CVCT9,656 HIA\$7,930/HIA\$7,930/HIAPopulation TasP for all HIV + cohabitating men and women identified by individual HTC17,872 HIA\$12,891/HIA\$12,891/HIA  Behaviour changeEnns et al. (2011) [@bb0355]Increased monogamy77 (8 ⋅ 7%) HIANR\--3%Eswatini: \$4,090 ⋅ 00\
Tanzania: \$1,090 ⋅ 00\
Uganda: \$717 ⋅ 50\
Zambia: \$1,145 ⋅ 00High-risk partnership reduction115 (11 ⋅ 7%) HIANR\--Untargeted partnership reduction76 (8 ⋅ 9%) HIANR\--  StructuralFieno et al. (2014) [@bb0360]Cash transfer at \$5 monthly benefit3,400 HIA\$1,650/HIA\$1,919/HIANRSouth Africa: \$6,560 ⋅ 00Cash transfer at \$10 monthly benefit4,250 HIA\$2,640/HIA\$3,071/HIACash transfer at \$20 monthly benefit5,100 HIA\$4,400/HIA\$5,118/HIARemme et al. (2014) [@bb0365]Long-term benefits of 18-month cash transfer trial93,600 HIV DALYs averted\$297/HIV DALY averted\$345/HIV DALY avertedNRMalawi: \$349 ⋅ 13Rutstein et al. (2014) [@bb0370]Passive ReferralRef.Ref.\--NRMalawi: \$349 ⋅ 13Provider Notification27 ⋅ 5 HIAICER = \$3,560/HIA\$4,080/HIAContract Notification0 ⋅ 4 HIAICER = \$51,421/HIA\$58,941/HIA[^4][^5][^6][^7][^8][^9][^10][^11][^12][^13][^14][^15][^16]

The median CERs for each intervention type were as follows: \$2967 per HIA and \$-388/DALY averted for VMMC, \$13,267 per HIA and \$799 per QALY gained for PrEP, \$7903 per HIA and \$890 per DALY averted for TasP, \$1421 per HIA and \$191 per DALY averted or QALY gained for PMTCT, \$1143 per HIA and \$392/DALY averted for other biomedical interventions (microbicides, vaccination, praziquantel treatment, combination prevention, condom distribution), and \$3575/HIA and \$345/DALY averted for structural interventions (partner notification, cash transfer programs). For several of the intervention types, scenarios that prioritized specific sub-populations based on age and/or risk factors were more cost-effective than scenarios that targeted the general population ([Fig. 2](#f0010){ref-type="fig"}, [Fig. 3](#f0015){ref-type="fig"}, [Fig. 4](#f0020){ref-type="fig"}, [Fig. 5](#f0025){ref-type="fig"}, [Fig. 6](#f0030){ref-type="fig"}, [Fig. 7](#f0035){ref-type="fig"}).Fig. 2Cost-effectiveness measures of VMMC interventions.Data points reflect the measures from VMMC studies reporting cost per HIV infection averted (above) and cost per DALY averted (below). Points represent study-specific cost-effectiveness estimates; error bars represent estimate ranges, if provided in study results.Fig. 2Fig. 3Cost-effectiveness measures of PrEP interventions.Data points reflect the measures from PrEP studies reporting cost per HIV infection averted (above) and cost per DALY averted or QALY gained (below). Points represent study-specific cost-effectiveness estimates; error bars represent estimate ranges, if provided in study results.Fig. 3Fig. 4Cost-effectiveness measures of TasP interventions.Data points reflect the measures from TasP studies reporting cost per HIV infection averted (above) and cost per DALY averted (below). Points represent study-specific cost-effectiveness estimates; error bars represent estimate ranges, if provided in study results.Fig. 4Fig. 5Cost-effectiveness measures of PMTCT interventions.Data points reflect the measures from PMTCT studies reporting cost per HIV infection averted (above) and cost per DALY averted or QALY gained (below). Points represent study-specific cost-effectiveness estimates.Fig. 5Fig. 6Cost-effectiveness measures of biomedical interventions.Data points reflect the measures from miscellaneous biomedical studies reporting cost per HIV infection averted (above) and cost per DALY averted or QALY gained (below). Points represent study-specific cost-effectiveness estimates; error bars represent estimate ranges, if provided in study results.Fig. 6Fig. 7Cost-effectiveness measures of structural interventions.Data points reflect the measures from structural intervention studies reporting cost per HIV infection averted (above) and cost per DALY averted (below). Points represent study-specific cost-effectiveness estimates; error bars represent estimate ranges, if provided in study results.Fig. 7

[Table 3](#t0015){ref-type="table"} and [Fig. 8](#f0040){ref-type="fig"} provide the results of the quality assessment of each study using the CHEERS checklist.Table 3CHEERS quality assessment, by intervention type.Table 31234567891011a11b1213a13b14151617181920a20b21222324Binagwaho et al. (2010) [@bb0075]Y^⁎^YYYYYYYYN^⁎^YN/A^⁎^N/AN/AYNP^⁎^YNYYN/AYN/AYNYNjeuhmeli et al. (2011) [@bb0080]NYYYYYNYYYN/AYN/AN/AYNYYNYYN/AYN/AYYYUthman et al. (2011) [@bb0085]YYYYYYYYPYN/ANN/AN/AYYYYYYYN/AYN/AYNNDuffy et al. (2013) [@bb0090]YYYYYYNYYNPN/AN/AYN/AYNYPPYN/AN/AN/AYNYMenon et al. (2014) [@bb0095]NYYYYNNPYPNN/AN/AYN/AYYYNYYNN/AN/AYYYAwad et al. (2015) [@bb0100]NYYYYNYYYYN/AYN/AN/AYNYYYNYN/AYN/AYYYAwad et al. (2015) [@bb0105]NYYYYYYYYYN/AYN/AN/AYNYYYYYN/AYN/AYYYHaacker et al. (2016) [@bb0110]YYYYYNYNYPN/AYN/AYYYYYYNYN/AYN/AYYYKripke et al. (2016) [@bb0115]PPYYYPYYPNN/ANPN/AYNYPNNYN/APYYYYKripke et al. (2016) [@bb0120]YPYYYNYYPYN/AYN/AN/AYPPPPPPN/AYN/AYYYKripke et al. (2016) [@bb0125]NPYPPNNPPPN/ANN/AN/AYPYPPNYN/AYYYYYKripke et al. (2016) [@bb0130]NPYYYNPYPYN/ANN/AN/AYPYYNNPN/AYYYYYKripke et al. (2016) [@bb0135]NPPYYNNYPYN/APN/AN/AYYPPYNYN/AYYYYYNjeuhmeli et al. (2016) [@bb0140]PPYPYNYYPYN/APN/AN/AYPYPPNYN/APN/AYYY  PrEPPretorius et al. (2010) [@bb0145]YYYYYNYPNPYN/ANN/APNYYYYPN/AYN/AYYYHallett et al. (2011) [@bb0150]NYYYPNYNPYN/AYNN/APNYYYYYN/APN/AYYYCremin et al. (2013) [@bb0155]NPYYYYYYPPN/AYN/AN/AYYYYYYPN/AYN/AYYYNichols et al. (2013) [@bb0160]YYYYYPYPPPN/APNN/APNYYYYYN/AYN/AYYYVerguet et al. (2013) [@bb0165]NYYPYNYYNPN/AYYN/APNYYYYYN/AYN/AYNYAlistar et al. (2014) [@bb0170]YYYPYNYYPPN/AYNN/AYNYYYYYN/AYN/AYYYNichols et al. (2014) [@bb0175]YYYYYNYYPPN/AYNN/APNPYYPYN/APN/AYYYCremin et al. (2015a) [@bb0180]NNYYYYYYPPYN/AN/AN/AYNYYPPYN/ANN/APYYCremin et al. (2015b) [@bb0185]YYYYYYYYPPN/AYN/AN/APNYYNYYN/ANN/APYYYing et al. (2015) [@bb0190]YYYYYYYYPPYN/ANN/AYYYNPNPN/ANN/AYYYGlaubius et al. (2016) [@bb0195]YYYYYYYYPPN/AYN/AN/AYYPYYYYN/AYN/AYYYWalensky et al. (2016) [@bb0200]YYYYYYYYPPN/APN/AN/AYYYYYYYN/AYN/AYYYCremin et al. (2017) [@bb0205]NYYYYYYYPPN/AYN/AN/AYPYYYPPN/APN/AYYY  TasPBarnighausen et al. (2012) [@bb0210]PPYPYNYYYPN/AYN/AN/APNYYYNYN/AYN/AYNYGranich et al. (2012) [@bb0215]YYYYYPYYYYN/APYN/AYYYYYYYN/AYN/AYYYSmith et al. (2015) [@bb0220]YYYYYYYYPYN/AYPYN/APYYYPYN/AYN/AYYYBershteyn et al. (2016) [@bb0225]NYYPYNPPPNN/ANNN/APNYYYNYN/AYYYYYYing et al. (2016) [@bb0230]NPYYYYYPPPYN/ANYN/AYPYYNYYN/AN/AYYY  PMTCTHalperin et al. (2009) [@bb0235]NYYPPYPNNYN/AYN/AN/AYNNYYYYN/ANN/AYYYNakakeeto et al. (2009) [@bb0240]PPPPPYYPPYN/AYN/AN/AYYYYNYPN/APN/AYYNOrlando et al. (2010) [@bb0245]YYYYYYYYYYYN/AYN/AYYNPPPYNN/AN/AYPNRobberstad et al. (2010) [@bb0250]YYYYYNYNPYNN/AYN/ANNPYPPPYN/AN/AYYNShah et al. (2011) [@bb0255]YPYpYYYYYN/AN/AYYN/AYYYYYYYN/AYN/AYYYKuznik et al. (2012) [@bb0260]YYYYYYYYYYN/ANYN/AYYYYYYYYN/AN/AYNYBinagwaho et al. (2013) [@bb0265]YPYYYYYYYYN/AYN/AN/AYPNYYYPN/AYYYNNFasawe et al. (2013) [@bb0270]YYYYYYYYPYN/AYPN/AYPYYYYYN/AYN/AYPNMaredza et al. (2013) [@bb0275]YYYYYYYYYYN/AYYN/AYYPYYYYN/AYN/AYNNGopalappa et al. (2014) [@bb0280]NYYYPNYYPPN/AYN/AN/AYPYYPYYN/ANN/AYYYIshikawa et al. (2014) [@bb0285]PYYYYYYYPYN/APYN/AYNYYYYYN/AYN/AYYYYu et al. (2014) [@bb0290]YYYYYNYYPYN/AYYN/AYYYYYYYN/AYN/AYYYZulliger et al. (2014) [@bb0295]YYPYYNYYYYYN/AYYN/AYNYPYYYN/AN/AYYYPrice et al. (2016) [@bb0300]YYYYYYYPPYN/AYYN/AYYPYYYYN/AYN/AYYYTweya et al. (2016) [@bb0305]YYYYYNYPPYN/AYNN/APPYYYYYN/AYN/AYYY  Other biomedicalVerguet et al. (2010) [@bb0310]YYYYPNYYYYN/AYYYYYYYYYYN/AYN/AYNYWilliams et al. (2011) [@bb0315]NPYNNNPPNYYN/APN/AYNYYYNYN/ANN/AYYYLong et al. (2013) [@bb0320]YYYYYNPYNYN/AYYYNPYYYYYN/AYN/AYYYMbah et al. (2013) [@bb0325]YPYYYYYPYYN/AYN/AYYYYYYYYN/AYN/APYYTerris-Prestholt et al. (2014) [@bb0330]YYYYYYYYPYN/AYNYYYYYYYYN/AYN/AYYYMvundura et al. (2015) [@bb0335]YYYNYNYYNYN/APN/AN/AYYYYNPYN/ANN/AYPYMoodley et al. (2016) [@bb0340]YYYYYYYYYYN/AYYYYYYYYYYN/AYN/AYYYMoodley et al. (2016) [@bb0345]YYYYYYYYYYYN/AN/AN/AYYYYYYYN/AYN/AYYYWall et al. (2018) [@bb0350]NPYPYYYYYYPN/AN/AYN/ANNPYPYYYN/AYYY  Behaviour ChangeEnns et al. (2011) [@bb0355]YYYYYYYYPPN/AYN/AN/APNYYYYYN/AYN/AYYY  StructuralFieno et al. (2014) [@bb0360]NNPYYNPPNYYN/AN/AYN/ANPYPYYNN/AN/AYNYRemme et al. (2014) [@bb0365]NPYYYYYPPYPN/AYYN/AYYYYYYYN/AN/AYYYRutstein et al. (2014) [@bb0370]YPYYYYYPNYYN/AN/AYN/AYYYYYYYN/AN/AYYN[^17][^18]Fig. 8Visual representation of CHEERS checklist evaluation.Green bars represent the number of studies that completely fulfilled the corresponding item of the CHEERS checklist. Blue bars represent the number of studies that did not fulfill an applicable item. Gray bars represent the number of studies that partially, but did not completely, fulfilled the CHEERS checklist item. Yellow bars represent number of studies for which the item was not applicable.Fig. 8

4. Discussion {#s0050}
=============

This review summarizes the evidence to date on recent studies of the cost-effectiveness of HIV prevention interventions and serves as an SSA-specific update to the 2009 review by Galarraga et al. [@bb0045] Results from this review illustrate that established interventions, such as VMMC and PMTCT, remain cost-effective, as previously found in the 2009 review. For newer prevention strategies, such as PrEP and TasP, many of the studies relied on various assumptions and scenarios that may not reflect reality.

The review found that PMTCT and VMMC interventions were the most cost-effective. Studies on PMTCT interventions, including HAART, infant feeding methods, expedited ART, and Option B + suggest that these strategies are very cost-effective [@bb0235], [@bb0245], [@bb0250], [@bb0270], [@bb0280], [@bb0285], [@bb0295]. These studies provide evidence supporting WHO guidelines of transitioning from Option A and of recommending PMTCT Option B and Option B +. When WHO began the policy transition from Option B to Option B + in 2013, the agency conducted a preliminary cost analysis to estimate the incremental cost of switching to the new policy [@bb0375]. The authors argued that researchers should develop additional cost-effectiveness models to appropriately evaluate the cost of the policy with programmatic data. A number of studies have since provided evidence supporting the policy decisions around Option B + [@bb0280], [@bb0285]. However, stakeholders should be mindful that implementation of strategies like Option B + raises concerns since many of these studies do not take into account initial costs and upfront investment required to scale up PMTCT programs to a level that can be considered cost-effective over an extended time period [@bb0305], [@bb0375]. Additionally, while the majority of PMTCT studies included in this review focused on Prong III, only one study addressed PMTCT Prong II by studying the expansion of family planning services as a cost-effective method to avert HIV infections through the prevention of unintended pregnancies [@bb0235]. This focus may reflect recent programmatic shifts towards PMTCT Prong III and treatment of HIV infected women, even though family planning is effective in reducing MTCT.

The VMMC studies included in this review agreed that the intervention was cost-effective. Seven different studies developed models that estimated cost effectiveness of VMMC at 80% coverage, which is a common target for many HIV prevention programs; however, achieving this level of coverage is often not feasible in many settings [@bb0080], [@bb0095], [@bb0115], [@bb0120], [@bb0125], [@bb0130], [@bb0135]. Additional studies exploring cost effectiveness at various levels of VMMC coverage may help inform decision makers in areas where 80% coverage would be difficult to attain. Multiple studies explored scenarios targeting VMMC at different age groups, with a consensus that prioritizing younger males is more favourable and cost-saving compared to targeting the general male adult population [@bb0075], [@bb0110], [@bb0120].

Similarly, a common conclusion was that PrEP strategies targeting specific risk groups were more cost-effective than general PrEP strategies [@bb0145], [@bb0160], [@bb0170], [@bb0175], [@bb0195]. Four studies found that PrEP was most cost-effective when using a prioritization strategy aimed at young individuals who are most at-risk, including having more than four partners and reporting low condom use [@bb0160], [@bb0170], [@bb0195], [@bb0205]. The majority of included PrEP studies were set in South Africa, a country that could perhaps better absorb the higher costs of PrEP implementation compared with others in the region. However, three studies in Zambia and Mozambique agreed that prioritizing high-risk individuals would create the most effective scenario for PrEP implementation, adding to the evidence that a targeted PrEP strategy could be feasible across country settings [@bb0160], [@bb0175], [@bb0180].

The assumption of 100% PrEP coverage considered in many studies may be difficult to implement [@bb0055], [@bb0070]. This scenario implies that every eligible individual would receive PrEP, which may not be realistic in settings where universal treatment has not even been realized. Many studies point out that achieving such a high level of PrEP coverage would be less cost-effective than simply increasing ART coverage. Accordingly, WHO issued recommendations in 2015 to provide PrEP as a prevention option to individuals at substantial risk of acquiring HIV in settings with high HIV incidence [@bb0380]. Although studies have shown that PrEP can be cost-effective when targeted towards high-risk groups and when assuming high adherence, it remains a challenging intervention due to high costs, ethical issues, and inequitable distribution [@bb0040].

The five studies included in this review were not in agreement with regard to the cost-effectiveness or the feasibility of TasP strategy; one study concluded that TasP was less cost-effective than a combination of VMMC and ART, which is already the standard practice in many sub-Saharan African settings [@bb0210]. From this review, it is unclear whether or not TasP would be more cost-effective in certain settings over others. Despite this uncertainty, many countries have already developed and implemented guidelines for TasP and universal test-and-treat (UTT) [@bb0385]. Healthcare investment to provide UTT services successfully is substantial, especially in extensive resource-constrained settings [@bb0390].

This review also included studies that explored cost-effectiveness of methods that are still in development and not currently available on the market, including long-acting PrEP injections, HIV vaccines, and microbicide gels. The findings from these studies suggest that these interventions would be cost-effective once accessible [@bb0310], [@bb0315], [@bb0320], [@bb0330], [@bb0340], [@bb0345]. Only one study included in this review considered the reduction of HIV incidence by estimating the intervention effect of schistosomiasis treatment. Mbah et al. showed that mass praziquantel administration would be a cost-effective approach to reduce HIV transmission. In addition to its affordability, praziquantel treatment is very safe, well tolerated, and easily administered, but it has not been explicitly considered as a HIV prevention intervention, as the link between HIV acquisition and schistosomiasis remains unclear [@bb0325].

The vast majority of the included studies determined cost-effectiveness based on the WHO-CHOICE guidance that considers interventions to cost-effective if the cost per DALY averted is between one and three times the study country\'s GDP per capita [@bb0395]. This threshold is becoming increasingly contested, as many experts believe that it does not consider governments\' ability to generate the appropriate resources or willingness to pay [@bb0400], [@bb0405]. Some studies have translated HIA to DALYs; we did not find a standard conversion that would be applicable to the various country settings [@bb0085]. Moreover, the usefulness of this type of threshold is especially important when discussing high cost interventions, such as PrEP and TasP. Although these prevention strategies may be considered cost-effective under certain assumptions, this may not always translate into feasible implementation. The GDP-based threshold is unrelated to national and donor HIV budgets, both of which are needed to understand an intervention\'s affordability. Thus, more information is need on whether many SSA countries would be able to implement a large-scale PrEP program, although its use as a main prevention strategy has been heavily emphasized in policy discussion [@bb0040]. Many countries are already struggling to provide universal ART, and adding a high-cost strategy may apply further pressure on resource limited prevention programs.

In the 2009 review, Galarraga et al. concluded that not enough information regarding cost-effectiveness of many prevention strategies existed for decision-making or policy change [@bb0045]. Their review included many cost-effectiveness studies on interventions for behaviour change, intravenous drug use (IDU) harm reduction, and information, education, and communication. The present review found only two studies on behaviour change and structural interventions, with most recently published studies focusing on biomedical interventions. This shift represents a reflection of changing priorities of the international donor community and emerging technology available from pharmaceutical companies. The authors mentioned the lack of cost-effectiveness studies on vulnerable groups, such as men who have sex with men (MSM) and female sex workers (FSW). Similarly, the current review found only one study focusing on FSWs, although there are published studies on these populations in settings outside of Africa [@bb0330], [@bb0410]. The continuing dearth of studies on these vulnerable populations in sub-Saharan Africa ought to be addressed by future research, as costing studies can inform policymaking.

Several limitations were recognized while conducting this review. First, behavioral and structural interventions, like partner concurrency reduction and condom use, have historically been included in HIV prevention programs [@bb0355]. Although the studies in this paper suggest that these strategies are cost-effective, most analyses do not separate the effect of behaviour change on HIV incidence from other interventions, thus not allowing us to understand the effectiveness of these interventions in isolation [@bb0335], [@bb0355]. Second, comparability across studies was difficult since parameters, settings, and assumptions vary. Unless studies present cost-effectiveness estimates using the same assumptions, base year, time horizon, and discount rate, we should take caution when comparing study estimates.

Third, many of the cost-effectiveness studies offer evidence for a specific intervention in a number of scenarios, but few address the potential effects of an intervention in scenarios outside the scope of the study. This makes it difficult to generalize a study\'s results to other country settings, creating an obstacle for policy makers in determining how and when a single intervention is the most cost-effective for a specific country. The limited geographic coverage among the studies additionally does not allow for broad generalizability. South Africa was the setting in 24 of the 60 studies (40%) and just three countries (South Africa, Zambia, and, Malawi) comprise over 60% of the studies.

Lastly, this review is not immune to publication bias. Studies that do not demonstrate interventions as cost-effective are less likely to be submitted to peer-reviewed journals or to be published by journals [@bb0415]. It is possible that some cost-effectiveness results of current HIV interventions are not available to key policy makers, which poses a large problem. Despite the aforementioned limitations, this review included studies of good quality, highlighting the strength of the available evidence.

The large number of studies included in this review reflects the increasing importance of considering cost-effectiveness as a factor in implementing HIV prevention interventions in sub-Saharan Africa. The studies demonstrated intervention cost-effectiveness under a variety of scenarios and emphasized interventions targeting high-risk populations. In contrast to the 2009 Galarraga review, which concluded that sufficient cost-effectiveness data did not exist to inform large-scale decision making, the results from emergent, more robust and varied costing studies may serve as an aid to inform evidence-based decisions. Key stakeholders, such as international donors and government agencies, should consider cost-effectiveness results and affordability when developing national guidelines and protocols for HIV prevention to maximize prevention impact under resource constraints. However, important gaps in the research persist: a lack of focus on vulnerable populations remains an important concern in this region, and additional studies that discuss the cost-effectiveness of different combinations of interventions are needed to reflect the reality of HIV programs in this region [@bb0420].
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[^1]: World Bank 2017 HIV prevalence estimates

[^2]: Health care payer perspective refers to costs incurred or saved by the governmental healthcare system; Donor perspective refers to costs incurred of saved by international donors; Program and service delivery perspective refers to costs incurred by a stakeholders implementing HIV program; Societal perspective refers to all of society regardless of the payer; Private perspective takes into account the costs incurred by service providers

[^3]: Abbreviations: ANC = antenatal care clinic; ARV = antiretrovirals; ART = antiretroviral therapy; FSW = female sex worker; HAART = highly active antiretroviral therapy; KZN = KwaZulu-Natal, South Africa; MC = male circumcision; MMC = medical male circumcision; PMTCT = prevention of mother-to-child transmission; PrEP = pre-exposure prophylaxis; TasP = treatment as prevention; VMMC = voluntary medical male circumcision; WHO = World Health Organization; yo = years old.

[^4]: Country GDP estimates retrieved from International Monetary Fund, World Economic Outlook.

[^5]: ART coverage means HIV treatment for people with CD4 \< 350 cells/μL and TasP coverage means HIV treatment for people with CD4 ≥ 350 cells/μL.

[^6]: PMTCT Plus refers to a HAART intervention for all HIV infected women during pregnancy and lactation, regardless of CD4 count, according to 2009 WHO guidelines.

[^7]: Negative value indicates an intervention was less effective than base case.

[^8]: Not reported for infant only infections averted.

[^9]: Women in remedy cohort received HIV testing and standard treatment only after delivery.

[^10]: Extended dominated excludes any intervention that has a higher ICER than more effective interventions.

[^11]: Women in the promptly treated cohort received HIV testing and treatment at some point during pregnancy.
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[^18]: Item Checklist: 1. Title; 2. Abstract; 3. Introduction 4. Target Population; 5. Setting and Location; 6. Study Perspective; 7. Comparators; 8. Time Horizon; 9. Discount Rate; 10. Choice of health outcomes; 11a. Measurement of effectiveness (single study-based estimates); 11b. Measurement of effectiveness (synthesis-based estimates); 12. Measurement of performance based outcomes; 13a. Estimating Resources and Costs (single study-based economic evaluation); 13b. Estimating Resources and Costs (model-based economic evaluation); 14. Currency, Price, Conversion; 15. Model Choice; 16. Assumptions; 17. Analytical Methods; 18. Study Parameters; 19. Incremental Costs and Outcomes; 20a. Characterizing Uncertainty (single study-based economic evaluation); 20b. Characterizing Uncertainty (model-based economic evaluation); 21. Heterogeneity; 22. Study Findings; 23. Funding; 24. Conflicts of Interest
